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Gingival overgrowth can cause dental occlusion and
seriously interfere with mastication, speech, and dental
hygiene. It is observed in 25 to 81 % of renal transplant
patients treated with cyclosporine A (CsA). CsA-induced
gingival overgrowth (CIGO) is caused by quantitative
alteration of the extracellular matrix components,
particularly collagen. However, the molecular mechanisms
involved in the pathogenesis of CIGO remain poorly
understood, despite intense clinical and laboratory
investigations. The aim of the present work is to identify
differentially expressed genes closely associated with CIGO.
Human gingival fibroblasts were isolated by primary
explant culture of gingival tissues from five healthy subjects
(HGFs) and two patients with the CIGO (CIGO-HGFs).
The proliferative activity of CsA-treated HGFs and CIGO-
HGFs was examined using the MTT assay. The
identification of differentially expressed genes in CsA-
treated CIGO-HGF was performed by differential display
reverse transcriptase-polymerase chain reaction (RT-PCR)
followed by DNA sequencing. CsA significantly increased
the proliferation of two HGFs and two CIGO-HGFs,
whereas three HGFs were not affected. Seven genes,
including the beta subunit of prolyl 4-hydroxylase (P4HB)
and testican 1, were upregulated by CsA in a highly
proliferative CIGO-HGF. The increased P4HB and
testican-1 mRNA levels were confirmed in CsA-treated
CIGO-HGFs by semiquantitative RT-PCR. Furthermore,
CsA increased type I collagen mRNA levels and suppressed
MMP-2 mRNA levels, which are regulated by P4HB and
testican-1, respectively. These results suggest that CsA may
induce gingival overgrowth through the upregulation of
P4HB and testican-1, resulting in the accumulation of
extracellular matrix components.
Key words: cyclosporine A; gingival overgrowth; beta
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Introduction
Cyclosporin A (CsA) is the most frequently used
immunosuppressor for the prevention of the organ
transplant rejection because of its low toxicity and potential
application in the management of a variety of systemic
disorders (Wysocki et al., 1983). Despite its considerable
success as a truly selective immunosuppressant drug, CsA
therapy is also associated with various adverse side effects
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such as nephropathy, hypertension, hepatotoxicity, neurotoxicity,
and gingival overgrowth (Tyldesley and Rotter, 1984).
Gingival overgrowth is observed between 25 to 81 % of
renal transplant patients treated with CsA. The enlargement
of gingival tissue can allow the accumulation of oral
bacteria into the pockets followed by the marginal
periodontitis and systemic infection in some cases.
Therefore, the better understanding of the pathogenesis of
the drug-induced gingival overgrowth is one of the
important subjects in clinical periodontology.
Clinical and cellular studies associated with CsA-induced
gingival overgrowth (CIGO) have demonstrated that CsA
affects the gingival fibroblast proliferation (Bartold, 1989;
Park et al., 2007) and connective tissue extracellular matrix
(ECM) accumulation, resulting from the abnormal synthesis
of collagen and other ECM molecules (Tipton et al., 1991)
and the decreases of the activity of collagen degrading
enzymes (Barber et al., 1992; Schincaglia et al., 1992). In
addition, it has been suggested that the impaired ability of
matrix degradation may play an important role in CIGO
rather than the increase of the number of fibroblasts (Nares
et al., 1996). Therefore, studies have focused on interstitial
collagens (Barber et al., 1992; Gagliano et al., 2004) and
matrix metalloproteinases (MMPs) as the main targets of
CsA (Bolzani et al., 2000).
Type I collagen is the main collagen species in all layers of
gingival connective tissue. Its content is determined by a
dynamic balance between synthesis and degradation, and
disturbances in collagen turnover may be important in the
development of GO. While a stimulating effect of CsA on
type I collagen synthesis has been reported (Schincaglia et
al., 1992; Gagliano et al. 2004), some workers demon-
strated that collagen synthesis was not affected (Bartold et
al., 1989) or inhibited by CsA (Barber et al., 1992). Analysis
of immunohistological preparations in cases of GO
demonstrated that type IV collagen was present in
significantly higher amounts in the CsA-treated gingiva
than in healthy gingiva, but type III collagen was not
significantly greater (Bonnaure-Mallet et al., 1995).
MMP family of zinc-dependent endopeptidases is
responsible for the remodeling of ECM in both
physiological and pathological processes (Cotrim et al.,
2002). Although MMPs are broadly divided into interstitial
collagenases, gelatinases, stromelysins, and membrane-
type MMPs, each group can degrade essentially the ECM
components. Evidence has been shown that CsA inhibits
significantly the activity of MMP-1, MMP-2 and MMP-3
(Bolzani et al., 2000; Yamada et al., 2000; Cotrim et al.,
2002; Hyland et al., 2003; Gagliano et al., 2004; Kim et al.,
2008), thereby contributing to the extracellular matrix
accumulation found in CIGO. However, the molecular
mechanisms involved in the pathogenesis of CIGO remain
poorly understood despite intense clinical and laboratory
investigation. The aim of the present work is to explore the
molecular mechanisms of CIGO by identifying the
differentially expressed genes closely associated with
CIGO.
Materials and Methods
Chemicals
Cyclosporin A (CsA), 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl-tetrazolium bromide (MTT), dimethylsulfoxide
(DMSO), isopropanol and chloroform were purchased from
Sigma-Aldrich (St. Louis, MO, USA). Dulbecco’s modified
Eagle’s medium (DMEM), fetal bovine serum (FBS),
phosphate buffered saline (PBS), antibiotic-antimycotic
mixture (10,000 units/ml penicillin G sodium, 10,000 µg/ml
streptomycin sulfate, and 25 µg/ml amphotericin B) and
trypsin-EDTA solution (0.25 % trypsin, 1 mM EDTA) were
purchased from Invitrogen Corporation (Grand Island, NY,
USA).
Cell cultures
Human gingival fibroblasts were obtained using primary
explant culture of gingival tissues from 5 healthy subjects
without evidences of inflammation, hyperplasia or the
history of taking drugs associated with gingival overgrowth,
and from 2 patients with the CsA-induced gingival
overgrowth, respectively. The donors were from 27 to 65
years old. Informed consent was obtained from each
subject. The protocol for the study was approved by
Institutional Review Board of Yonsei University College of
Dentistry, Seoul, Korea. Gingival biopsies were washed
with sterile PBS and plated in 25 cm
2
 culture flasks, and
incubated with DMEM supplemented with 20 % heat-
inactivated FBS and 2 % antibiotic-antimycotic mixture at
37
o
C in a humidified atmosphere of 5 % CO2. When
reaching confluence, the cells were trypsinized with 0.25 %
trypsin containing 1 mM EDTA. All experiments were
performed with cells between the third and sixth passages. 
Cell proliferation assay
Human gingival fibroblasts from healthy subjects (HGFs) or
patients with CIGO (CIGO- HGFs) were seeded at 1 × 10
3
cells/well in DMEM containing 10 % FBS in 96-well plates.
24 h later, the medium was replaced to fresh 2 % FBS-
DMEM containing the various concentrations of CsA
(0, 0.1, 1.0, 10, 100 ng/ml), and the cells were cultured for 3
days and 5 days. CsA (1 mg/ml) was dissolved in DMSO
and diluted with 2 % FBS-DMEM. Control cells received
0.01 % DMSO alone. When cells reached confluence, a
MTT solution (final concentration: 0.5 mg/ml) was added to
each well and incubated for 4 h at 37
o
C. The MTT solution
was removed and the remaining formazan products were
dissolved by 100 µl of DMSO. Absorbance was measured
at 570 nm using spectrophotometric microplate reader (Bio-
Rad, Hercules, CA, USA).
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Differential display reverse transcriptase-polymerase
chain reaction (DDRT-PCR)
Total cellular RNA was isolated from CIGO-HGFs treated
with CsA (0, 0.1, 1.0, 10 ng/ml) using TRIzol reagent (Life
technologies, Austria). DDRT-PCR was performed using
the RNAimage kit (GenHunter Corp., Nashville, TN, USA).
The DNase I-treated total RNA pools (200 ng per each
group) were subjected to reverse transcription in reverse
transcriptase buffer (25 mM Tris-HCl, pH 8.3, 37.6 mM
KCl, 1.5 mg MgCl2 and 5 mM DTT) with 5 unit/µl of
MMLV-reverse transcriptase, 20 µM dNTP mix and 0.2 µM
of guanosine-anchored oligo(dT) primer (HT11-G). The
cDNA samples were used for PCR in dilution of 1:10. PCR
(20 µl) was performed in PCR buffer (10 mM Tris-HCl, pH
8.4, 50 mM KCl, 1.5 mM MgCl2 and 0.001 % gelatin)
containing 2 µM dNTP, 0.2 µM of HT11-G, 0.2 µM of
arbitrary primer (from H-AP1 to H-AP10), 0.2 µl of α-
[
33
P]dATP (2000 Ci/mmole), and 0.05 unit/µl of AmpliTaq
DNA Polymerase (Perkin Elmer Inc., Wellesley, MA,
USA). The thermocycler (GeneAmp PCR System 9700,
Applied Biosystems, Australia) was programmed as
follows: 40 cycles at 94
o
C for 30 sec, 40
o
C for 2 min, and
72
o
C for 30 sec, and terminated with a final extension at
72
o
C for 5 min. Radiolabeled PCR products were separated
on 6 % denaturing polyacrylamide gel and the bands
visualized by autoradiography.
Cloning and DNA sequencing
The differentially expressed cDNA fragments identified
on the autoradiogram were excised from the gel, eluted by
boiling in water and reamplified by PCR with the same set
of primers and conditions used in DD-PCR. The reamplified
PCR products were cloned in PCR-TRAP vector using
PCR-TRAP cloning system (GenHunter Corp.) according
to the manufacturer’s instructions. Sequencing of cloned
cDNAs was performed at Takara Korea Biomedical Inc.
(Suwon, Korea) and the sequence alignment was performed
in GenBank of National Center for Biotechnology
Information (NCBI) using standard nucleotide-nucleotide
BLAST (blastn) program (http://www.ncbi.nlm.nih.gov/
BLAST/) and all EMBL libraries using Fasta3 program
(http://www.ebi.ac.uk/fasta3/).
RT-PCR
Semi-quantitative RT-PCR was performed to confirm the
results from DDRT-PCR and to investigate mRNA
expression levels of type I collagen and metalloproteinase-2
(MMP-2) in CIGO-HGFs treated by CsA. First-strand
cDNA was synthesized with 1 µg of total RNAs and 1 µM
of oligo-dT15 primer using MMLV Reverse Transcriptase
(Promega, Medison, CA, USA). Using the recombinant Taq
DNA polymerase kit (Takara, Shiga, Japan), PCR was
performed with 0.5 µg of first-strand cDNA and 20 pmole
of primers (Table 1). PCR reaction consisted of initial
denaturation at 94
o
C for 3 min, 30 cycles at 94
o
C for 40 sec,
52
o
C for 40 sec (61
o
C for type I collagen), and 72
o
C for 1
min, and final extension at 72
o
C for 10 min. The amplified
PCR products were electrophoresed on a 1.5 %-2 % agarose
gel and visualized by staining the gel with ethidium
bromide. The mRNA expression level of each gene was
normalized with that of glyceraldehyde-3-phsophate
dehydrogenase (GAPDH).
Statistical Analysis
Statistical analysis of the data was performed using the
unpaired Student’s t test. The p value less than 0.05 was
considered to be statistically significant.
Results
Among 5 HGFs isolated from 5 healthy subjects, the
proliferation of 2 HGFs was increased meaningly by CsA
treatment for 3 and 5days (Fig. 1A-a), whereas that of 3
HGFs were not changed (Fig.1A-b). In contrast, all CIGO-
HGFs from 2 patients with gingival overgrowth showed
significantly increased proliferation when cultured with
CsA for 3 and 5 days (Fig. 1B).
To identify the differentially expressed genes associated
with CsA-induced proliferation in CIGO-HGFs, DDRT-
PCR was performed. As described in Table 2, seven genes
were upregulated by CsA treatment. Among them, the
increased mRNA expression levels of β subunit of prolyl 4-
hydroxylase (P4HB; Fig. 2A) and testican-1 (Fig. 2B) were
confirmed in CsA-induced highly proliferated CIGO-HGFs
Table 1. Primers.
Target genes Sequences Product size(bp)
Testican 1
    Forward  5’-TGTGTGACCCAGGACTACCA-3’
    Reverse   5’-ACTTGTTGAACATCCAGCCC-3’
478
P4HB
    Forward  5’-GGAGATGACCAAGTACAAGC-3’
    Reverse   5’-GGCTTTGCGTATTACAGTTC-3’
573
MMP-2
    Forward  5’-GTCGCCCATCATCAAGTTC-3’
    Reverse   5’-CTCCCAAGGTCCATAGCTCA-3’
557
Type I collagen
    Forward  5’-GGCGGCCAGGGCTCCGAC-3’
    Reverse   5’-CCACGGGGTCTGGTCCTTAA-3’
347
GAPDH
    Forward  5’-GTCAGTGGTGGACCTGACCT-3’
    Reverse   5’-AGGGGTCTACATGGCAACTG-3’
420
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by semiquantitive RT-PCR. Furthermore, mRNA expression
levels of type I collagen (Fig. 3A) and MMP-2 (Fig. 3B)
were increased in CsA-induced highly proliferated CIGO-
HGFs.
Discussion
Gingival overgrowth (GO), seriously interfering with
occlusion, mastication, speech and dental hygiene, is
Fig. 1. The effect of CsA on the proliferation of human gingival fibroblasts. Five HGFs and two CIGO-HGFs were stimulated with CsA at
the indicated doses for 3 and 5 days, respectively. Cell proliferation was measured by MTT assay. Graph A shows the representatives of two
HGFs indicating the increased proliferation by CsA treatment (a), and three HGFs which were not affected by CsA treatment (b). The graph
B represents CsA-induced proliferation of two CIGO-HGFs. The results are expressed as the mean ± SE of triplicate assays. *P < 0.05,
**P < 0.01.
Table 2. Genes upregulated by CsA treatment in CIGO-HGFs.
Clone
No.
Acession No. Definition Homology
3 NM_000918.2
Homo sapiens procollagen-proline,
oxoglutarate 4-dioxygenase
(proline 4-hydroxylase), beta polypeptide 
(protein disulfide isomerase; thyroid hormone
binding protein p55) (P4HB), mRNA 
100
15 AF231124.1 Homo sapiens testican 1 mRNA, complete cds 96
17 NM_000366.3 Homo sapiens tropomyosin 1 (alpha) (TPM1), mRNA 100
24 AAN37426.1
NADH dehydrogenase (ubiquinone) 
(EC1.6.5.3) chain 2-human mitochondrion,
partial (84 %)
94
33 M94314.1
Homo sapiens ribosomal protein L30, mRNA, 
complete cds
95
34 BC000690.1
Homo sapiens ribosomal protein L24, mRNA 
(cDNA clone MGC:2240 IMAGE:3349215), 
complete cds
100
36 BC040354.1
Homo sapiens, similar to caldesmon 1,
clone MGC:21352 IMAGE:4753285, mRNA, 
complete cds
100
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observed in a significant number of cases treated with
immunosuppressants (CsA, etc), antiepileptics (phenytoin,
etc) and calcium channel antagonists (nifedipine, etc). It has
been known that the drugs resulting in GO directly or
indirectly influence both the growth and function of the
gingival fibroblasts, which play an important role in ECM
turnover through the production of both matrix
macromolecules and matrix-degrading enzymes such as
MMPs (Nares et al., 1996; Atilla and Kutukculer, 1998;
Swarga et al., 2001). Up to date, various cell culture studies
have focused on connective tissue extracellular matrix
accumulation to elucidate the pathogenesis of gingival
Fig. 2. mRNA expression of P4HB and testican 1 in CsA-stimulated CIGO-HGFs. Semi-quantitative RT-PCR was performed to investigate
mRNA expression levels of P4HB and testican I as described in Materials and Methods.
Fig. 3. mRNA expression of type I collagen and MMP-2 in CsA-stimulated CIGO-HGFs. Semi-quantitative RT-PCR was performed to
investigate mRNA expression levels of P4HB and type I collagen as described in Materials and Methods.
210 Seong-Hee Park, et al.
overgrowth.
In this study, CsA treatment increased the proliferation of
two HGFs and all CIGO-HGFs, but that of three HGFs was
not changed by CsA, when cultured between 0.1 ng/ml and
100 ng/ml of CsA for 3 and 5 days. Two CIGO-HGFs,
rather than HGFs, proliferated more significantly by CsA
stimulation. These results suggest that the priming of the
gingival tissue with cyclosporin in human can lead to the
increased susceptibility of the fibroblasts on CsA in vitro.
To investigate the molecular mechanisms by which CsA
increases the proliferation of human gingival fibroblasts and
extracellular matrix accumulation, the differentially
expressed genes following CsA treatment were identified in
a highly proliferating CIGO-HGF by CsA stimulation using
DDRT-PCR. Among seven genes upregulated by CsA
treatment, P4HB is a multifunctional protein regarded as the
protein disulfide isomerase (PDI) (Koivu et al., 1987). PDI
catalyzes the formation of disulfide bonds in type I and II
procollagens (Koivu and Myllylä, 1987) and prolyl 4-
hydroxylase (Koivu and Myllylä, 1986), a key enzyme of
collagen synthesis. The function of PDI as a component of
prolyl 4-hydroxylase appears to be to maintain the catalytic
subunits in a soluble form rather than directly participating
in catalysis, and thereby participates during proline
hydroxylation (John et al., 1993). PDI also acts as a
molecular chaperone assisting the folding of polypeptides
(Cai et al., 1994). More recently, the association of PDI with
type I procollagen has been proposed to lead to endoplasmic
reticulum retention of type I procollagen, which is
composed of two proα1(I) chains and one proα2(I) chain
and intracellularly degraded immediately after its synthesis,
in corneal endothelial cells (Ko et al., 2004). Furthermore, it
has been reported that the proyl 4-hydroxylase inhibitor is
more effective for the inhibition of proliferation than for
inhibition of collagen synthesis of rat hepatic stellate cells
(Aoyagi et al., 2002). Therefore, our data demonstrate that
the overexpression of PDI mRNA by CsA in CIGO-HGFs
may increase cell proliferation while producing collagen, by
stabilizing prolyl 4-hydroxylase and delaying the intracellu-
lar degradation of type I procollagen. In addition, these
results can provide the molecular basis of other in vitro
studies that CsA causes a significant increase in the level of
type I procollagen and cell proliferation (Bolzani et al.,
2000).
Testican-1 is a highly conserved chimeric proteoglycan
carrying both chondroitin sulfate and heparan sulfate chains
(Alliei et al., 1993). Testican-1 has been shown to inhibit the
activation of pro-MMP-2 by either MT1-MMP or MT3-
MMP (Nakada et al., 2001) as well as the activity of
lysosomal enzyme cathepsin L (Bocock et al., 2003),
regulating the degradation of extracellular matrices (Nakada
et al., 2003). Recent studies have reported that the reduced
activity of cathepsin-L (Yamada et al., 2000) and matrix
metalloproteinases (Bozani et al., 2000; Cotrim et al., 2002;
Hyland et al., 2003; Gangliano et al., 2004) by CsA,
resulting in the inhibition of protein degradation in gingival
connective tissues, plays important roles in the pathogenesis
of CIGO. Our result suggests that the suppression of MMP-
2 expression in CIGO can be due to the overexpression of
testican-1 by CsA. Furthermore, alterations of type I
collagen and MMP-2 expression following the upregulation
of P4HB and testican-1 mRNA levels were assessed in
CIGO-HGF cells treated with CsA by RT-PCR. We
confirmed that CsA increased type I collagen mRNA levels
and suppressed MMP-2 mRNA levels.
In conclusion, CsA may induce the gingival overgrowth
through the upregulation of P4HB and testican-1, resulting
in the increase of collagen synthesis and the accumulation of
extracellular matrix components by inhibiting MMP-2
activity, in patients receiving CsA therapy. This is the first
report demonstrating that the accumulation of collagen in
CIGO regulates by P4HB and testican-1.
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